感性突破+理性体验，趋势洞察下的全新数字营销之道。 《中国化妆品》杂志｜苏悦怡 在国际品牌眼中，中国市场的无限潜力不仅体现在庞大的消费规模，更源自极具创造力的线上营销生态。以李佳琦为代表的头部主播，已经从"带货"角色 跃升为拥有百万级粉丝的意见领袖，其直播间场景化脚本和互动营销模式，屡屡将美妆新品推上销量高峰；而在TikTok上，欧美的KOL、KOC也纷纷效 仿，借力美妆产品种草短视频、直播带货等多元玩法，获得流量与销量。正是这种基于流量驱动的数字营销模式，让国际品牌在全球市场的竞争格局中， 看到了将中国经验复制到海外的可行性。 然而，伴随流量红利的消退，消费者正从"冲动买买买"走向"理性体验主义"。不再满足于一味追求"性价比"或"网红推荐"，他们更关注产品背后的成分科 学和使用感受。抖音博主、植美馥予品牌创始人田甜认为："粉丝进直播间，不是单纯想听我说'好用'与否，而是期待看到成分解析、功效验证，以及最 有效的使用方案——比如使用护肤水后是否需要轻拍，搭配哪些精华效果更佳等。"在这种趋势下，品牌若要赢得长期信任，必须以内容为入口，从"买 它"扩展到"懂它"。 正因如此，《中国化妆品》杂志在今年CBE展会上， ...

Core Insights - The "Academician Expert Enterprise Tour" initiative in Xiantao City is fostering collaboration between enterprises and academic institutions to enhance industrial development through targeted technological solutions [1][2][3] Group 1: Medical Supplies Industry - Xiantao City is addressing precision control challenges in the production of medical sand velvet cloth, reducing production error from ±0.1mm to ±0.03mm, achieving international advanced standards [2] - The upgraded production line for medical sand velvet cloth has increased capacity by 60%, improved efficiency of medical protective clothing production by 75%, and reduced order delivery time by 50% [2] - The quality compliance rate for products has risen from 92% to 99%, successfully passing EU MDR certification, thus opening doors to international high-end markets [2] Group 2: Food Processing Industry - Traditional food products, such as salted egg yolks, have seen significant quality improvements, with microbial contamination rates reduced by 95% through collaboration with academic teams [3] - The restructuring of supply chain information management systems in food companies has facilitated digital transformation, breaking down information silos across procurement, production, and logistics [3] - Xiantao City has reported 15 technical needs from enterprises in 2024, leading to successful matches between five companies and expert teams for collaborative projects [3] Group 3: Overall Impact - The initiative has collected 67 technical needs from enterprises, engaged 37 provincial experts, and provided technical services to 33 companies, resolving 92 operational challenges and facilitating 47 technology transfers [3] - The dual approach of government support, enterprise needs, and expert empowerment is continuously stimulating innovation within Xiantao's industries, contributing to high-quality economic development [3]

资料显示，朗晖石化此前就是蓝帆医疗的子公司。2014年，蓝帆医疗以1.5亿元将朗晖石化100%股权转 让给山东蓝帆化工有限公司(后变更为朗晖石化控制的企业)。彼时，朗晖石化为重资产亏损企业，其"6 万吨/年特种糊树脂项目"投产仅半年即被剥离。 然而，剥离后的朗晖石化与蓝帆医疗仍保持密切的合作关联性。2022年至2024年，朗晖石化连续三年位 列蓝帆医疗第一大供应商，采购金额分别为4.99亿元、4.96亿元和5.77亿元，占年度采购总额的 15.27%、12.88%和12.52%。采购内容主要为PVC手套原材料糊树脂及增塑剂。如今为什么要逆袭成为 蓝帆医疗控股股东？这背后又有怎样的资本战略安排？ 有业内人士认为，本次权益变动，可能与朗晖石化近年来推进上市计划有关。 资料显示，朗晖石化自2021年9月启动上市辅导，最新一期辅导时间为2025年1月1日至3月31日。不过， 朗晖石化在辅导过程中仍面临内控制度完善、独立董事聘任等问题。 近日，医疗器械行业巨头蓝帆医疗（002382）(002382.SZ)公告了间接控股股东变更暨权益变动的消 息。 因山东朗晖石化向公司控股股东蓝帆投资增资取得其52.0395%的股权，导 ...

Core Viewpoint - The recent change in the shareholding structure of Bluestar Medical has raised concerns among investors regarding potential interests transfer and the implications of the new indirect controlling shareholder, Langhui Chemical [3][4][5] Group 1: Shareholding Changes - Langhui Chemical has acquired a controlling stake in Bluestar Medical's major shareholder, Zibo Bluestar Investment, through a capital increase, diluting the stake of Bluestar Group from 98% to 47.0013% [5][6] - Despite the change in indirect control, the actual controller, Li Zhenping, remains unchanged, and the company asserts that this does not affect the control or business structure of Bluestar Medical [5][6][9] Group 2: Financial Performance and Transactions - Langhui Chemical, previously a loss-making subsidiary, has transformed into a leading enterprise in the plasticizer and resin sector, with revenues of approximately 12.15 billion, 12.69 billion, and 13.42 billion from 2022 to 2024 [6][11] - Bluestar Medical has reported continuous losses over the past three years, with revenues of approximately 4.9 billion, 4.93 billion, and 6.25 billion, and net losses of approximately 372 million, 568 million, and 446 million during the same period [11] Group 3: Supply Chain and Procurement - Langhui Chemical has been the largest supplier for Bluestar Medical over the past three years, with procurement amounts of approximately 499 million, 496 million, and 577 million, accounting for 15.27%, 12.88%, and 12.52% of total annual procurement [9][10] - Bluestar Medical plans to procure approximately 635 million from Langhui Chemical in 2025, which is significantly higher than from other suppliers, indicating a reliance on this supplier despite the commitment to reduce related transactions [10][11]

证券代码：002382 证券简称：蓝帆医疗 蓝帆医疗股份有限公司投资者关系活动记录表 编号：202502 | | □特定对象调研□分析师会议 | | | | | --- | --- | --- | --- | --- | | 投资者关系活动 | □媒体采访■业绩说明会 | | | | | 类别 | □新闻发布会□路演活动 | | | | | | □现场参观 | | | | | | □其他 | | | | | 参与单位名称及 | 参与公司 2024 年度网上业绩说明会的投资者 | | | | | 人员姓名 | | | | | | 时间 | 日(周五)下午 2025 5 15:00-17:00 | 年 | 月 | 23 | | 地点 | "价值在线"平台（https://eseb.cn/1nJGAJOocNO） | | | | | | 董事长：刘文静女士 | | | | | | 董事、总裁：钟舒乔先生 | | | | | 上市公司接待人 | 董事、心脑血管事业部总经理：于苏华先生 | | | | | 员姓名 | 独立董事：乔贵涛先生 | | | | | | 副总裁、首席财务官：崔运涛先生 | | | | | | ...

蓝帆医疗股份有限公司 上市公司名称：蓝帆医疗股份有限公司 股票上市地点：深圳证券交易所 股票简称：蓝帆医疗 股票代码：002382 信息披露义务人名称：山东朗晖石油化学股份有限公司 住所：淄博市临淄区金山镇经济开发区内 通讯地址：山东省淄博市临淄区一诺路 48 号 股份变动性质：同一控制人下的股份变动（增加） 签署日期：2025 年 5 月 16 日 信息披露义务人声明 一、本报告书系信息披露义务人依据《中华人民共和国证券法》、《上市公司 收购管理办法》、《公开发行证券的公司信息披露内容与格式准则第 15 号—权益 变动报告书》、《公开发行证券的公司信息披露内容与格式准则第 16 号—上市公 司收购报告书》及其他相关的法律、法规和规范性文件编制。 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违反 信息披露义务人章程及内部规则中的任何条款，或与之相冲突。 三、依据《中华人民共和国证券法》、《上市公司收购管理办法》的规定，本 报告书已全面披露了信息披露义务人在蓝帆医疗股份有限公司中拥有权益的股份 变动情况。截至本报告书签署日，除本报告书披露的信息外，信息披露义务人没有 通过任何其他方式增加或减 ...

Core Points - The company held its 2024 Annual General Meeting to discuss various proposals and reports, including financial performance and governance matters [1][5][6] Group 1: Financial Performance - In 2024, the company achieved a revenue of 602.62 million yuan, an increase of 0.42% compared to the previous year [24] - The net profit attributable to shareholders was -190.67 million yuan, a decrease of 4.33 million yuan from the previous year [7][22] - The company proposed not to distribute profits for 2024 due to the negative net profit, maintaining a focus on sustainable operations [22][26] Group 2: Governance and Reporting - The board of directors and the supervisory board presented their respective work reports, emphasizing compliance with legal and regulatory requirements [7][16] - The company plans to enhance its governance structure and internal control systems to ensure effective decision-making and operational efficiency [10][19] Group 3: Asset Management - The company proposed to recognize an asset impairment provision totaling 37.26 million yuan for various assets, including accounts receivable and inventory [29][30] - The company reported a significant reduction in various liabilities, including a 72.77% decrease in other current liabilities [27][28] Group 4: Future Financing - The company intends to apply for a comprehensive financing credit limit of up to 1 billion yuan from banks and financial institutions to support business development [30][31] - The company currently has an external guarantee balance of 312.61 million yuan, which exceeds its audited net assets [31]

多元业务韧性生长 心脑血管事业部2025年一季度持续保持高速增长态势。一季报显示，公司心脑血管事业部一季度销售收 入超过3.6亿元，较去年同期增长约26%。从公司投资者交流记录披露的内容可知，中国、南亚、拉美 地区心内科行业增速为10%—15%，欧美发达国家心内科行业增速约为5%，公司心脑血管业务增速超过 行业平均水平。这主要得益于公司推出的新产品持续放量，据公开信息查询，公司2024年共有十余款心 脑血管产品获批上市（含孵化、代理产品）。随着研发成果加速转化，公司产品线丰富，带动心脑血管 整体业务规模提升，同时，依托成熟的全球化、全渠道网络布局优势，新产品得以快速渗透市场，推动 心脑血管业务规模快速扩张。 4月28日晚间，蓝帆医疗（002382）发布2025年一季度报告。报告期内，公司实现营收14.78亿元，同比 增长1.59%；实现归母净利润7702.23万元，较上年同期实现大幅增长。同时，公司一季度经营性现金流 净额达到1.98亿元，同比由负转正，环比也大幅提升。 公司业绩的大幅增长，主要得益于两个方面：一方面，公司主业经营状况向好，扣非后的归母净利润较 上年同期减亏51.02%；另一方面，公司参股投资 ...

正式报名：首届全球心血管大会 | 重磅亮点 合作伙伴征集：2025全球手术机器人大会 2025年4月26日， 鱼跃医疗 发布了2024年年报以及2025一季报。 | | | 2023 年 | | 本年比 | | | | --- | --- | --- | --- | --- | --- | --- | | | | | | 上年增 | 2022 年 | | | | 2024 年 | | | 视 | | | | | | 调整前 | 调整后 | 调整后 | 调整前 | 调整后 | | 营业收入 | 7.565.819.017.28 | 7.971.734.452.47 | 7.971.734.452.47 | -5.09% | 7.101.679.159.74 | 7.101.679.159.74 | | (元) | | | | | | | | 归属于上市 公司股东的 | 1.805.700.655.26 | 2.395.853.276.49 | 2.395.853.276.49 | -24.63% | 1.595.037.435.14 | 1.595.037.435.14 | | 净利润 | | | | | | ...

中国向缅甸提供紧急人道主义地震救灾援助 此前，云南省地方救援队已第一时间抵达仰光。 百万用户都在看 突发！中国资产，集体异动！发生了什么？ 直线涨停！刚刚，三大巨头，重磅来袭！ 中国结算，三箭齐发！ "国家队"，出手！集体飙升！ 事关降息！重磅来袭！ 利好来袭！上海，重磅发布！这个板块集体拉升！ 违法和不良信息举报电话：0755-83514034 中国政府首批援助物资计划31号启运。中方还将视缅方需要继续提供援助。 邮箱：bwb@stcn.com 来源：国家国际发展合作署 3月29日，国家国际发展合作署新闻发言人李明应询表示，缅甸发生强震灾害，造成重大人员伤亡和财产损 失。应缅甸政府请求，中国政府决定向缅甸提供1亿元人民币紧急人道主义地震救灾援助，派出两支救援队， 提供帐篷、毛毯、急救包、食品、饮用水等灾区急需物资。 责编： 刘珺宇 首支救援队已于3月29日抵达仰光，将及时奔赴灾区开展现场救助。国合署副署长刘俊峰等赴机场送行。 校对： 刘榕枝 ...